Gibson Dunn advises KKR on investment in Coriolis Pharma
Frankfurt, London and Munich — KKR Health Care Growth Fund II has made an investment in German biopharmaceutical research and development company Coriolis Pharma. As part of the transaction, Coriolis Pharma will enter into a strategic growth partnership with Frontier Biosolutions, a global pharmaceutical services platform newly formed by KKR and Flerie Invest AB.
KKR’s investment will enable Coriolis to embark on the next phase of growth in its core business, expand its portfolio of services along the value chain, strengthen its global presence and continue to integrate AI-based technologies.
Coriolis is expected to gain access to KKR’s global healthcare network and Frontier Biosolutions to expand Coriolis’ global operations and growth plans in innovative, high-value formulation research and development services.
“Since Coriolis was founded 15 years ago, our vision has been to revolutionize the biopharmaceutical drug development process by integrating innovative digital formulation approaches from development through commercial products,” said Coriolis co-founders and board members Michael and Thomas Wiggenhorn. The cooperation with KKR should enable major steps forward in this regard and further expand the company’s scientific leadership position, he said.
The Gibson Dunn team, led by London partner and co-head of the private equity practice in Europe Wim De Vlieger and Frankfurt partners Dr. Wilhelm Reinhardt and Dr. Jan Schubert, included London counsel Dr. Jakob Egle and associates Sonja Ruttmann, Dr. Dennis Seifarth (both Munich), Lisa Hollfelder (Frankfurt) and Gisele Zouein (London). Brussels antitrust and competition law partner Attila Borsos and London associates Ben Nunez and Robert Albertson Kill as well as corporate counsel Dr. Birgit Friedl and associate Dr. Marcus Geiss (both Munich) supported the team. In Munich, partner Kai Gesing and associates Christoph Jacob and Yannick Oberacker advised on IP issues, while Frankfurt finance counsel Alexander Klein and associate Bastiaan Wolters advised on financing issues.
About Gibson Dunn
Gibson, Dunn & Crutcher LLP is one of the leading international law firms and is ranked among the top law firms worldwide in industry surveys and by authoritative publications. With more than 1,800 lawyers in 20 offices, the firm has a global presence in all major economic regions. Gibson Dunn offices are located in Abu Dhabi, Brussels, Century City, Dallas, Denver, Dubai, Frankfurt, Hong Kong, Houston, London, Los Angeles, Munich, New York, Orange County, Palo Alto, Paris, Beijing, San Francisco, Singapore and Washington, D.C. For more information, visit www.gibsondunn.com.